A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 6, 1997, Pages 390-401

  Ortensi, Graciela ^a   Gladstein, Julio ^a   Valli, Hector ^a   Tesone, Pedro A ^a,b  

^a HOSPITAL RAMOS MEJÍA   (Argentina)

^b NONE   (Argentina)

Author keywords

Elderly; Hypercholesterolemia; Policosanol; Simvastatin

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATURAL PRODUCT; POLICOSANOL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GERIATRIC PATIENT; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0030857721     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80099-9     Document Type: Article

References (63)

1. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenings of the Multiple Risk Factor Intervention Trial. JAMA. 1986;256:2823-2827.
2. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in the incidence of coronary heart disease. JAMA. 1984;251: 351-364.
3. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in the incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
4. Frick MH, Elo D, Haapa K, et al. Helsinki Heart Study: Primary-intervention trial with gemfibrozil in middle-aged men with dislipidemia. NEJM. 1987;317:1237-1245.
5. Tesone PA, Asciutto A, Ortensi G, Gladstein J. Lipid profile assessment in the elderly. Rev Soc Argent Nutrition. 1992;3:37-40.
6. Karvonen MJ. Prevention of cardiovascular disease among elderly. Bull WHO. 1988;66: 7-14.
7. Benfante R, Reed D. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA. 1990;263:393-396.
8. Bilheimer DW. Clinical consideration regarding treatment of hypercholesterolemia in the elderly. Atherosclerosis. 1991;91(Suppl):S35-S57.
9. Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: Resolving the treatment dilemma. Ann Intern Med. 1990;112:780-792.
10. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet. 1989;17:236-241.
11. Goldberg PB, Roberts J. Pharmacological basis for developing rational drug regimens for elderly patients. Med Clin North Am. 1983;67:315-331.
12. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med. 1991;114:956-958.
13. Arruzazabala ML, Carbajal D, Más R, et al. Efecto del policosanol sobre el perfil lipídico de conejos normocolesterolémicos. Arch Ven Farmacol Ter. 1992;11:80-86.
14. Rodríguez C, Mesa R, Más R, et al. Estudio del efecto sobre lipidos y lipoproteínas séricos y de la tolerancia al tratamiento oral con dosis crecientes de policosanol en monos (Macaca arctoides). Arch Ven Farmacol Ter. 1992;11:74-79.
15. Menéndez R, Fraga V, Sotolongo V, et al. Efecto de la administración oral del policosanol sobre el metabolismo lipídico de ratas normocolesterolémicas. Rev Mex Cien Farm. 1993; 24:16-18.
16. Menéndez R, Fernández I, Del Río A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res. 1994;27:199-203.
17. Hernández F, Illnait J, Más R, et al. Effect of ateromixol (policosanol) on serum lipids and lipoproteins in healthy volunteers. Curr Ther Res. 1992;51:1-8.
18. Castaño G, Zardoya R, Illnait J, et al. Efectos del tratamiento con ateromixol (PPG) (5 mg) en pacientes con hiperlipoproteinemia tipo II. Prog Cien Méd. 1991;5:21-28.
19. Pons P, Más R, Illnait J, et al. Efficacy and safety of policosanol in patients with primary hypercholesterolemia. Curr Ther Res. 1992;52:507-513.
20. Soltero I, Fuenmayor I, Colmenares J. Estudio comparativo doble ciego de la eficacia y tolerancia del policosanol vs bezafibrato en pacientes con hiperlipidemias tipo II. Arch Ven Farmacol Ter. 1993;12:71-76.
21. Aneiros E, Calderón B, Más R, et al. Effects of successive dose increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther Res. 1993;54:304-312.
22. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393-397.
23. Pons P, Rodríguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. J Clin Pharmacol Res. 1994;14:27-33.
24. Pons P, Rodríguez M, Más R, et al. One year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res. 1994;55:1084-1092.
25. Aneiros E, Más R, Calderón B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res. 1995;56:176-182.
26. Castaño G, Más R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res. 1995;56:296-304.
27. Canetti M, Moreira M, Illnait J, et al. One year study on the effect of policosanol (5 mg-twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Adv Ther. 1995;12:245-254.
28. Canetti M, Moreira M, Más R, et al. A two year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia. Int J Clin Pharmacol Res. 1997;15:159-165.
29. Alemán CL, Rodeiro I, Noa M, et al. Acute, subchronical and chronic toxicity of policosanol in rats. In: Abstracts of the Sixth International Congress of Toxicology; June 28-July 3 1992; Rome, Italy; p. 248.
30. Ferná;ndez SI, Rendón A, de las Cajigas A, et al. Estudio genotoxico del ateromixol (PPG), un nuevo medicamento hipolipemiante. Rev Cienc Biol. 1991;22:98-101.
31. Rodríguez MD, García H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutag. 1994;14:107-113.
32. Alemán CL, Más R, Hernández C, et al. A 12 month study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett. 1994;70:77-87.
33. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in beagle dogs: One year study. Toxicol Lett. 1994;73:81-90.
34. Rodrígues C, Mesa R, Más R, et al. Effect of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem Toxicol. 1994;32:565-575.
35. Alemán CL, Más R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study. Teratog Carcinog Mutag. 1994;14:239-249.
36. Alemán C, Noa M, Cerejido E, et al. Carcinogenicity of policosanol in mice: An 18 month study. Food Chem Toxicol. 1995;33:573-578.
37. Pons P, Jiménez A, Rodríguez M, et al. Effects of policosanol in elderly hypercholesterolemic patients. Curr Ther Res. 1993;53:265-269.
38. Castaño G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hyperlipoproteinemia: A 12-month study. Curr Ther Res. 1995;56: 819-828.
39. Alberts AW, Chen J, Kuron G, et al. Mevinolin, a highly potent competitive inhibitor of hydroxymethyl glutaryl-coenzyme A reductase and a cholesterol lowering agent. Proc Natl Acad Sci USA. 1980;77:3957-3961.
40. Illingworth DR. Therapeutic use of lovastatin in the treatment of hypercholesterolemia. Clin Ther. 1994;16:2-26.
41. Matti J, Tikkanen MD, Eski A, et al. Current pharmacologic treatment of elevated serum cholesterol. Circulation. 1987;76:529-533.
42. Mitchel YB. The long-term tolerability profile of lovastatin and simvastatin. Atherosclerosis. 1992;97(Suppl):S33-S39.
43. Walker JF. Simvastatin: The clinical profile. Am J Med. 1989;87(Suppl 4A):44S-48S.
44. Farnier M, and the French Study Group. Comparison of simvastatin and ciprofibrate in the treatment of primary hypercholesterolaemia - a French multicentre study. Atherosclerosis. 1992;97(Suppl):S59-S66.
45. Pietro DA, Alexander S, Mantell G, et al. (Simvastatin Multicenter Study Group II). Effects of simvastatin and probucol in hypercholesterolemia. Am J Cardiol. 1989;63:682-686.
46. Tikkanen MJ, Bocanegra TS, Walker JF, et al. Comparison of low doses of simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol: A multicenter study. Am J Med. 1989;87(Suppl 4A):47S-49S.
47. Schulzack P, Bojanovski M, Jochim A, et al. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolemia. Lancet. 1988;1:611-613.
48. Farnier M, and the French Study Group. Comparison of simvastatin and ciprofibrate in the treatment of hypercholesterolemia. Atherosclerosis. 1992;97:59-66.
49. Ziegler O, Drouin P. Safety, tolerability and efficacy of simvastatin and fenofibrate - a multicenter study. Cardiology. 1990;77:50-57.
50. Farnier M, Bonnefous F, Debbas N, et al. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med. 1994;154:441-449.
51. Kuhn P, Darioli R, Bovet P, et al. Dose-dependent lipid-lowering effects of simvastatin (MK-733) in the elderly. Curr Ther Res. 1989;46:381-389.
52. Boccuzzi SJ, Keegan ME, Hirsch LJ, et al. Long term experience with simvastatin. Drug Invest. 1993;5:135-140.
53. Malini PL, de Divitiis O, di Somma S, et al. A comparative study of simvastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 1992; 97(Suppl):S41-S47.
54. Mölgaard J, Lundh BJ, Von Schenck H, et al. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia. Atherosclerosis. 1991;91(Suppl):S21-S28.
55. The European Study Group. Efficacy and safety of simvastatin and pravastatin in patients with primary hypercholesterolemia (a comparative study in different countries). Am J Cardiol. 1992;70:1-7.
56. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem. 1981;27:838-841.
57. Friedewald WT, Levy RI, Friederickson SD. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without preparative ultracentrifugue. Clin Chem. 1972;18:499-502.
58. Illingworth DR. An overview of lipid lowering drugs. Drugs. 1988;36(Suppl 3):63-71.
59. Stalenhoff ARH, Marc JTM, Stuyt PMJ. Efficacy and tolerability of simvastatin (MK-733). Am J Med. 1989;87(Suppl 4A):4A-395-4A-435.
60. Volpe R, Ginnetti MG, Urbinati GC, et al. Efficacy and safety of pravastatin and simvastatin in patients with primary hypercholesterolemia compared in a cross-over study. In: 3rd International Symposium on treatment of severe dylipoproteinemia in the prevention of coronary heart disease, Munich. Basel: Karger; 1990:271-279.
61. Volpe R, Area M, Ginnetti MG, et al. The efficacy and safety of pravastatin and simvastatin in patients with primary hypercholesterolemia. Curr Ther Res. 1992;51:422-430.
62. Volpe R, Area M, Ginnetti MG, et al. Efficacy and safety of simvastatin in long-term treatment of severe primary hypercholesterolemia. In: Halpem MJ, ed. Molecular Biology of Atherosclerosis. John Libbey and Company Ltd.; 1992:619-621.
63. Nakandakare E, Garcia RC, Rocha JC, et al. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis. 1990;85:211-217.